jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Anti Phospholipid Antibody (APL) - IgG

Immunity
image

Report in 12Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

These antibodies can increase the risk of blood clots, miscarriages, and autoimmune diseases, especially Antiphospholipid Syndrome (APS)

499825

40% OFF

Anti-Phospholipid Antibody (APL) - IgG Test Guide

  • Why is it done?
    • Detects IgG class anti-phospholipid antibodies that increase blood clotting risk and may cause thrombosis or pregnancy complications
    • Diagnosis of Antiphospholipid Syndrome (APS) - a hypercoagulable condition associated with autoimmune disease
    • Investigation of recurrent thrombotic events (deep vein thrombosis, pulmonary embolism, arterial thrombosis)
    • Evaluation of unexplained pregnancy losses, including recurrent miscarriages or fetal deaths
    • Assessment of patients with systemic lupus erythematosus (SLE) or other autoimmune conditions
    • Evaluation of thrombosis occurring in unusual sites or at young age without typical risk factors
    • Monitoring and re-testing for confirmation 12 weeks after initial positive result per diagnostic criteria
  • Normal Range
    • Normal (Negative) Result: Less than 7 GPL units/mL (GPL = Glycerol-3-Phosphate Lipoprotein)
    • Borderline/Weak Positive: 7-20 GPL units/mL - suggestive of APL presence but requires confirmation
    • Moderate Positive: 20-80 GPL units/mL - significant level associated with increased thrombotic risk
    • High Positive: Greater than 80 GPL units/mL - strong positive associated with highest thrombotic and obstetric complications
    • Units: GPL units/mL (Glycerol-3-Phosphate Lipoprotein units per milliliter)
    • Interpretation Key: Negative values indicate absence of pathogenic IgG anti-phospholipid antibodies. Positive results suggest presence of antibodies with potential for thrombosis or obstetric complications.
  • Interpretation
    • Negative Result (< 7 GPL units/mL): APL IgG antibodies not detected; low probability of APS diagnosis. Does not exclude other thrombotic or obstetric conditions.
    • Borderline Positive (7-20 GPL units/mL): Weak positive result requiring repeat testing. Clinical significance uncertain; recommendations suggest retesting in 12 weeks for diagnostic confirmation. May indicate recent infection or transient antibodies.
    • Moderate Positive (20-80 GPL units/mL): Clinically significant APL antibodies present. Supports APS diagnosis when combined with clinical criteria. Associated with moderately increased thrombotic risk and pregnancy complications.
    • High Positive (> 80 GPL units/mL): Strong evidence of significant APL antibodies. Strongly associated with APS diagnosis and significantly elevated thrombotic risk. Patients at highest risk for venous and arterial thrombosis and severe obstetric complications.
    • Factors Affecting Results: Acute infections, malignancy, medications (warfarin, heparin - do not affect antibody levels), recent thrombotic events, and proximity to acute illness may transiently elevate results. IgG antibodies persist longer than IgM class.
    • Clinical Significance Patterns: Triple positive (APL IgG + IgM + lupus anticoagulant) indicates highest disease severity. Single positive IgG with clinical features requires APS diagnosis consideration. Persistently positive results after 12 weeks confirm pathogenic antibodies versus transient findings.
  • Associated Organs
    • Primary Systems Involved: Vascular/circulatory system (blood vessels and blood), hematologic system (blood coagulation), immune system (autoimmunity)
    • Antiphospholipid Syndrome (APS): Systemic autoimmune disorder where anti-phospholipid antibodies cause inappropriate blood clotting affecting multiple organs
    • Vascular Thrombotic Complications: Deep vein thrombosis (legs), pulmonary embolism (lungs), arterial stroke (brain), myocardial infarction (heart), mesenteric thrombosis (intestines), retinal artery/vein thrombosis (eyes)
    • Obstetric Manifestations: Recurrent first-trimester miscarriages, fetal death in utero, severe preeclampsia, placental insufficiency, intrauterine growth restriction, fetal thrombosis
    • Associated Autoimmune Diseases: Systemic lupus erythematosus (SLE) - most common, Sjögren's syndrome, rheumatoid arthritis, autoimmune thyroid disease, inflammatory bowel disease
    • Catastrophic APS (Rare but Severe): Multiple simultaneous thromboses affecting kidneys, lungs, heart, brain, adrenal glands with high mortality rate if untreated
    • Other Associated Complications: Thrombocytopenia (low platelets), heart valve disease, nephropathy (kidney disease), cognitive dysfunction, skin necrosis, livedo reticularis
  • Follow-up Tests
    • Confirmatory APL Testing (Recommended 12 weeks after initial positive): Repeat APL IgG test, Anti-phospholipid IgM test, Lupus anticoagulant test, Anti-cardiolipin antibodies
    • Coagulation Studies: Prothrombin time (PT), Activated partial thromboplastin time (aPTT), Platelet count, Fibrinogen level, D-dimer
    • Autoimmune Disease Screening: Antinuclear antibody (ANA), Anti-Smith (anti-Sm), Anti-double stranded DNA (anti-dsDNA), Complement levels (C3, C4), Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)
    • Imaging Studies for Thrombosis Evaluation: Doppler ultrasound (venous thrombosis), CT angiography (pulmonary embolism), Brain MRI/CT (stroke), Echocardiography (cardiac involvement)
    • Obstetric-Related Testing: Serial ultrasound during pregnancy, Fetal monitoring, Uterine artery Doppler studies, Placental function assessment
    • Organ Function Monitoring: Renal function tests (creatinine, BUN), Liver function tests, Chest imaging, Urinalysis for proteinuria
    • Monitoring Frequency: Initial confirmation at 12 weeks; then periodic monitoring (every 6-12 months) for patients on anticoagulation; more frequent testing during acute thrombotic events or pregnancy
    • Anti-Beta-2 Glycoprotein I Antibodies: More specific for APS diagnosis than cardiolipin antibodies; provides additional pathogenic information
  • Fasting Required?
    • Fasting Required: No
    • Food and Drink: No fasting required; normal eating and drinking before blood draw is acceptable
    • Medications: Continue all regular medications including anticoagulants (warfarin, heparin), antiplatelet drugs (aspirin), and immunosuppressants - these do not interfere with test results
    • Sample Collection Timing: Blood sample can be collected at any time of day. For patients with suspected acute thrombosis, draw sample as soon as possible after event.
    • Special Instructions: Avoid prolonged fist clenching during blood draw to prevent hemoconcentration. Blood collected in appropriate citrate tube (typically 3.2% sodium citrate). Handle specimen gently to prevent hemolysis.
    • Repeat Testing Guidelines: If initial result is positive, must wait minimum 12 weeks before repeat testing for confirmation per Sydney classification criteria for APS diagnosis
    • Stress and Hydration: Maintain normal hydration status before test. Stress does not significantly affect APL antibody levels, but overall health maintenance is recommended.

How our test process works!

customers
customers